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ABSTRACT: Anisotropic colloidal hybrid nanoparticles
exhibit superior optical and physical properties compared to
their counterparts with regular architectures. We herein
developed a controlled, stepwise strategy to build novel,
anisotropic, branched, gold nanoarchitectures (Au-tripods)
with predetermined composition and morphology for
bioimaging. The resultant Au-tripods with size less than 20
nm showed great promise as contrast agents for in vivo
photoacoustic imaging (PAI). We further identified Au-tripods
with two possible configurations as high-absorbance nanoma-
terials from various gold multipods using a numerical simulation analysis. The PAI signals were linearly correlated with their
concentrations after subcutaneous injection. The in vivo biodistribution of Au-tripods favorable for molecular imaging was
confirmed using small animal positron emission tomography (PET). Intravenous administration of cyclic Arg-Gly-Asp-D-Phe-Cys
(RGDfC) peptide conjugated Au-tripods (RGD-Au-tripods) to U87MG tumor-bearing mice showed PAI contrasts in tumors
almost 3-fold higher than for the blocking group. PAI results correlated well with the corresponding PET images. Quantitative
biodistribution data revealed that 7.9% ID/g of RGD-Au-tripods had accumulated in the U87MG tumor after 24 h post-injection.
A pilot mouse toxicology study confirmed that no evidence of significant acute or systemic toxicity was observed in
histopathological examination. Our study suggests that Au-tripods can be reliably synthesized through stringently controlled
chemical synthesis and could serve as a new generation of platform with high selectivity and sensitivity for multimodality
molecular imaging.
■ INTRODUCTION
Current biomedical nanotechnology has been aimed at
effectively imaging and characterizing abnormal biological
processes at the cellular or even molecular level in living
subjects.1−5 Successful progresses in the fundamental molecular
imaging research including instrumentations and image
construction/registration techniques greatly motivate the
innovations of imaging probes. As a relatively new molecular
imaging technique, photoacoustic imaging (PAI) has recently
attracted significant research interests.6 PAI takes advantage of
individual strengths of both optical and acoustic imaging while
largely overcoming the weaknesses associated with each
modality, providing functional and molecular information of
abnormalities with deep tissue penetration, high sensitivity, and
excellent spatial resolution.7 In addition to several endogenous
contrasts (such as melanin and hemoglobin),8 various light-
absorbing nanoparticles (including Au-based nanostructures,
carbon nanotubes, and nanodroplets) have been developed for
PAI contrast enhancement.9−25 Although there are some
nanoparticle-based exogenous agents particularly promising
for PAI,20,22 their potential toxicity is still under investigation,
and the improvement of their in vivo behavior remains a
challenge since most attempts to enhance the contrast effect
compromise their pharmacokinetic profile.
As one class of strong optical-absorption nanomaterials,
colloidal metallic nanostructures (NPs) have recently attracted
significant attention from diverse disciplines for many
biomedical applications.26−28 Many synthetic methods have
been developed for the construction of a variety of plasmonic
nanostructures with controllable size and uniform shape (for
instance, triangles, prisms, rods, cubes, shells, stars, and
cages),9−25,29 largely because the effect of induced-shape
anisotropy of these nanostructures results in the splitting of
the underlying surface plasmon enhancement (SPR) into
several shape-dependent modes, which could be accordingly
tuned within the near-infrared window (NIR, 650−950
nm).30−36 As representative anisotropic nanogeometries, Au-
nanorods and -nanocages have shown great promise as PAI
contrasts; however, they generally have relatively large particle
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sizes (∼50 nm), which could result in unfavorable in vivo
behavior and severely limit their application for targeted cancer
imaging.7,11,12,21,37 By making a compromise by trading
contrast effects for the ability to have preferable in vivo
behaviors, strenuous efforts have been made recently to
improve their targeting efficiency, and to control pharmacoki-
netics and biodistributions through variations of their sizes,
shapes, and surface properties. Although some metallic
nanostructures with complex shapes showed desired tumor
targeting efficiency without compromising optical properties,
great challenges still remain in the precise control of their
geometries and monodispersity.28−32
Recently, many colloidal hybrid nanostructures with
sophisticated architectures have been constructed from multiple
functional components either assembled using linkers or fused
together by solid-state interfaces.38 In order to build novel
hybrid nanostructures with optimal structure and morphology
for SPR, we herein developed a synthetic strategy to construct a
series of anisotropic gold-based nanomultipods, including
dipods, tripods, and tetrapods (Figure 1), with improved
yield and excellent quality in a predictable, controlled, and
stepwise manner. Among them, the gold tripods (Au tripods)
have relatively small sizes with a narrow size distribution and
display stringently controlled morphology and, more impor-
tantly, have well-defined absorptions in visible and NIR regions.
As a proof of concept, we further conjugated αvβ3 integrins
targeting the peptide, cyclic c(RGDfC) peptide,39 to PEGylated
Au-tripods (RGD-Au-tripods) and used this novel nanoprobe
as a PAI contrast agent to image tumor angiogenesis. The
tumor targeting efficacy and in vivo profile of PEGylated Au-
tripods (modified with different sizes of PEGs and/or RGD)
labeled with radionuclide 64Cu were evaluated in a subcuta-
neous αvβ3-positive U87MG glioblastoma xenograft model
using small animal positron emission tomography (PET).
Finally, PAI was performed to investigate the targeting and
imaging performance of RGD-Au-tripods as photoacoustic
contrast agents.
■ RESULTS
Construction and Characterization of Au-Tripods. By
sequentially applying a set of nucleation reactions and epitaxial
growth processes, we successfully built up four gold-based
nanostructures, comprising Au−Pt dumbbell, dipods, tripods,
and tetrapods, with predetermined composition and morphol-
ogy (Figure 1a). In this structure-guided approach, we chose
colloidal platinum (Pt) NPs as core seeds (or starting
materials) because they are highly monodisperse and their
sizes can be facilely tuned from 3 to 7 nm,40,41 and more
importantly, they have definite and rigid cubic shapes
(Supporting Information [SI], Figure S4). In order to tune
the sizes of Pt nanocrystals, we applied stepwise seed-mediated
growth processes to obtain monodisperse Pt nanocubes (SI
section C.1.1. and Figure S4). As-synthesized 4.9 nm Pt NPs
with truncated cubic shapes could preferably grew into
thermodynamically more stable morphologies (cubic 6.5 nm
Pt NPs) after an extra seed-mediated growth process. Similarly,
7.5 nm Pt NPs were obtained when 5.8 nm Pt NPs were used
as seeds. All Pt nanocubes have a very narrow size and shape
distribution (Figure S5 and Table S2). Due to excellent lattice
coherence between Pt and Au crystals in the fcc phase, the
epitaxial growth of gold preferentially occurs at the vertices of
cubic Pt seeds (SI section C.1.2), resulting in the formation of
various Au heterostructures (Figure 1). Typically, the epitaxial
growth of Au on 4.9 nm Pt seeds produced dumbbell-like Au−
Pt NPs. Use of 5.8 nm Pt NPs as seeds resulted in Au-dipods.
There are two geometrical isomers; one is linear and the other
is bent, corresponding to para and meta configurations,
respectively. Interestingly, we found that, unlike 7.5 nm Pt
NPs as seeds resulting in a mixture of tripods and tetrapods, 6.5
nm Pt seeds exclusively led to the formation of tripods with a
narrow distribution of size and shape (Figure 1b). The
statistical analysis suggested that a majority of resultant NPs
were Au-tripods (SI Figure S7−S9). To the best of our
knowledge, it is the first time for constructing novel Au tripods
with high yield and improved quality by sequentially applying a
Figure 1. Construction of gold multipods (including Au−Pt dumbbell NPs, Au-dipods, Au-tripods and Au-tetrapods). (a) Schematic showing the
stepwise syntheses of various gold multipods via a set of known nucleation reactions and epitaxial growth processes. Various gold multipods are
modeled by Lumerical FDTD Solution (Lumerical Solution Inc.). Considering the regioselectivity, several possible regioisomers are shown in the
bottom-left panel. (b) TEM images of the resultant gold multipods at different magnifications. HRTEM images of representative gold multipods are
shown in the bottom-right panels.
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set of known nucleation reactions and epitaxial growth
processes.
There are two geometrical isomers identified in the resultant
tripods; namely one with C3v symmetry is called as tripod-A
and the other with C2v symmetry is tripod-T (Figure 1a). The
steric accessibility determines the spatial distribution of Au
crystals on the Pt nanocubes (SI Scheme S2 and S3). There are
two meta positions favorable for the nucleation of incoming Au
crystals when an intermediate has a bent shape, thereby
resulting in the formation of tripod-A; there are six nucleation
positions equal to the incoming Au crystals in the case of a
linear intermediate, producing the other type of tripods (tripod-
T). The statistical analysis results showed that an amount of
tripod-T was finally obtained slightly higher than that of tripod-
A (60% vs 40% in the resultant tripods, n = 300, Figure 1a).
The sizes and shapes of various Au-multipods and each
component within NPs were determined by dynamic light
scattering (DLS) and TEM (SI Table S3 and Figure S9). The
Au-tripods showed the lowest circularity among the branched
NPs, largely due to their anisotropic nanostructures and surface
roughness.
The representative TEM and scanning transmission electron
microscope (STEM) images (Figure 2b−e) of Au-tripods
showed that well-crystallized interfaces were formed between
the Pt seeds and grown Au branches. The lattice fringes
between Pt seeds and Au branches shown in SI Figure S11 are
0.23 nm and related to (111) planes of either Pt or Au in the
fcc phase [2.260 Å for (111) plane of Pt, 2.355 Å for (111)
plane of Au]. STEM images clearly showed that each Au branch
epitaxially grew at one of the vertices of cubic Pt seeds. Two
types of tripods, tripod-T and tripod-A, were definitively
identified in the STEM images (Figure 2d−e). The forward and
inverse fast Fourier transforms (FFT) were further applied to
their HR-TEM images to distinguish Au branches and Pt core.
The right panel of Figure 2 shows the HR-TEM images of three
typical tripods (the first two belong to the type ‘tripod-T’; the
third one is ‘tripod-A’). The inset in diffractogram patterns
shows the splits of the (222) and (331) peaks into two spots:
one (blue) for Pt and the other (black) for Au crystal, because
of slightly different planar distances of the Pt and Au crystals.
Inverse FFT reconstructions of the Pt (bottom) or Au (top)
NPs using only their own reflections, [222], [331], [220], and
[111], provided the real-spatial distributions of Pt and Au in
tripods, respectively. Therefore, the lattice images coupled with
the forward and inverse fast Fourier transform further
confirmed the spatial configuration of Au branches and Pt
core within Au-tripods.
Optical Properties of Au-Tripods and Simulation. The
PAI requires contrast agents with relatively large absorption
cross section. A conventional UV−vis−NIR spectrometer can
Figure 2. HRTEM and STEM images of Au-tripods, and their Fourier transform and inverse Fourier transform analyses. (a) TEM image of typical
Au-tripods. There are two types of tripods: tripod-A (b) and tripod-T (c). (d,e) STEM images of two types of tripods. (f−h) HRTEM images of
typical tripod-T and its fast Fourier transform (FFT) and inverse fast Fourier transform (inverse FFT) analyses. The insets in (g) show the splits of
the (222) and (331) peaks into two spots: one for Pt and the other for Au crystal. Inverse FFT reconstructions of the Pt (bottom) or Au (top) NPs
using only the superlattice reflections, [222], [331], [220], and [111], are shown in (h). (i−k) HRTEM, FFT, and inverse FFT reconstruction of the
other tripod-T with different orientation. Inverse FFT reconstruction of the Pt (bottom) or Au (top) NPs using the superlattice reflections [222],
[331], [220], and [111]. (l−n) HRTEM, FFT, and inverse FFT reconstruction of tripod-A. The split of the (222) peaks is attributed to the
difference between Pt and Au crystals and is shown in the inset of (m). Inverse FFT reconstructions of the Pt (bottom) or Au (top) NPs using only
the superlattice reflections [222], [220], and [111] are shown in (n).
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measure the extinction spectra of nanostructures, which
comprise two components: scattering and absorption, even-
tually providing the extinction cross section (σe, σe = σa + σs,
where σa is absorption cross section and σs is scattering cross
section). As seen in Figure 3a, the Au-tripods have a much
stronger extinction peak in the NIR region, compared with the
other Au-multipods. There are two plasmon resonances at the
540 and 700 nm peaks in the region of 400 to 1000 nm. The
Figure 3. Optical properties of Au-tripods, and measurement and simulation of optical absorption cross sections of tripods. (a) UV−vis extinction
curves of various gold multipods (including Au−Pt dumbbell NPs, Au-dipods, Au-tripods, and Au-tetrapods) at the same sample weight (based on
ICP-MS). (b) UV−vis extinction curves of gold nanospheres, cubic platinum NPs, and gold nanorods (54 nm length and 18 nm diameter, more
information in the SI, sections C.2 and C.3). (c) The calculated absorption cross section of tripod-T as a function of ωx (the incident beam is
polarized along the z-axis, and the tripod-T is rotated around the x-axis. ωx is the angle between the e-field and the long axis of tripod-T. (d) The
calculated absorption cross section of tripod-A as a function of ωx (the incident beam is polarized along the z-axis, and the tripod-A is rotated around
the x-axis. ωx is the angle between the e-field and the side of tripod-A. Polarization dependence of the average electric field intensity of tripod-T (e)
and tripod-A (f). Electric field intensity contours in xz plane, xy plane, and yz plane at 700 nm were obtained from the FDTD calculations on both
tripod-T and tripod-A. The long axis of tripod-T is parallel to the z-axis; one side of tripod-A is parallel to the z-axis. The excitation polarization
relative to the z-axis is 0°. x and y represent the horizontal and vertical lengths of the calculated area.
Journal of the American Chemical Society Article
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540 nm feature corresponds to a quadrupole resonance out of
the plane of the gold tripods, and the 700 nm feature is
attributed to a dipole resonance in the plane of the Au-
tripods.20
The σa of Au-tripods was calculated using combined UV−
vis−NIR spectrometer and photoacoustic measurements.42
While UV−vis−NIR spectrometer measures the total extinction
coefficient, in photoacoustic imaging, the detected signal is
directly proportional to the absorption coefficient (μa) of the
NPs. Because the SPR peak of the tripods is tuned to 700 nm,
methylene blue is suitable as a reference dye to obtain the
calibration curve. On the basis of the linear relationship
between μa and photoacoustic signal amplitude and the known
σa of methylene blue (SI Figure S15), the photoacoustic signals
from Au-tripods with different concentrations were converted
into μa, and the σa of Au-tripods was calculated by dividing the
μa by the corresponding concentration of the Au-tripods. In the
calculation, the σa and σe of the tripods at 670 nm were 2.02 ±
0.03 × 10−16 and 2.06 ± 0.03 × 10−16 m−2, respectively (σa/σe
= 0.98). As a result, on a per-weight basis, the Au-tripods are
generally able to generate more contrast (33%) on PA images
within the NIR region compared to gold rods (SI Table S4).
To gain more insight into the localized surface plasmon
resonance (LSPR) spectra and to obtain better structural
optimization, we performed numerical analysis on various gold
multipods using a commercial finite difference time domain
(FDTD) simulation package (Lumerical Solution Inc.,
Canada). The Au-multipods are modeled as a cubic Pt core
with Au spheres (see detailed modeling in the SI sections B.3
and C.4). The corresponding geometrical parameters were
obtained from the previous results in SI Tables S2 and S3. The
contributions of absorption cross sections of two types of Au-
tripods (tripod-T and tripod-A) as a function of the rotated
angle around the x-axis were obtained using the FDTD
simulation and are shown in c and d of Figure 3. The calculated
absorption cross section maxima of tripod-T were at 530 and
710 nm, in good agreement with experimental data (a and c of
Figure 3), while theoretical absorption maximum peaks of
tripod-A occurred at 520 and 900 nm (very broad peak
centered at 900 nm). Using the FDTD method, we have further
studied the near-field optical properties of all gold multipods,
gold rods, and nanospheres (SI section C.4, Figures S16−S21).
The electric field intensity contours were calculated at the
excitation wavelength of 700 nm as the excitation polarization
was varied gradually from the longitudinal to transverse
directions. Similar to gold rods, the Au-tripods have a strong
polarization-dependent cross section. It was clear that under the
resonance excitation, the maximum field enhancement regions
were observed to rotate away from vertical tripod as the
excitation polarization rotated around the y-axis (SI Figure
S18). It is worth noting that the electric fields on the surface of
Au-tripods (especially Au-tripod-T) are ∼2−3 orders of
magnitude higher when compared to fields around spherical
gold nanoparticles at the same weight in the NIR range. As seen
in the Figure 3e,f and SI Figure S18, the edges of tripods and
the junctions between two Au−Au NPs on the Pt cores are
Figure 4. Small animal PET images and PET quantification of intravenous injected tripods with different surface functionalization in mice bearing
the U87MG human glioblastroma tumor. (a−c) Targeting of integrin αvβ3-postitive U87MG tumor in mice by RGD-functionalized tripods. Decay-
corrected whole-body coronal PET images of nude mice bearing human U87MG tumors at 1, 4, 24, and 48 h after injection of 3.7 MBq of 64Cu-
RGD-Au-tripod, 64Cu-RGD-Au-tripod with a blocking dose of c(RGDfC) (21 μmol of c(RGDfC)/kg of mouse body weight), and 64Cu−Au-tripod
(200 pmol/kg of mouse body weight, or 2 mg/kg of mouse body weight). (d,f) PET quantification of tumors and major organs after intravenous
injection to mice bearing subcutaneous U87MG glioma xenografts (n = 4 per group, data represent means ± SD). (g−i), Comparison of tumor and
major organ uptake of 64Cu-RGD-Au-tripod, 64Cu-RGD-Au-tripod with a blocking dose of c(RGDfC), and 64Cu−Au-tripod for a time period up to
48 h after intravenous injection to U87MG tumor-bearing mice (n = 4 per group). Data represent mean ± SD ** P < 0.01, *P < 0.05 (two-sided
Student’s t-test).
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locations of enhanced fields (also called hot spots), due to the
occurrence of coupled plasmons.
Surface Modification of Au-Tripods. In order to stabilize
the Au-tripods in the aqueous solution and provide the
capability for subsequent surface modification, we developed a
facile, versatile PEGylation strategy which can significantly
increase in vivo circulation time of resultant NPs and reduce
their reticuloendothelial system (RES) accumulation versus
uncoated counterparts. The PEGylation of Au-tripods involved
the formation of gold−thiolate bonds at the gold−sulfur
interface and the self-assembly of a monolayer on gold surface
(SI Scheme S1).43 The bidentate thiol-terminated polyethylene
glycol (PEG) chains facilitated subsequent immobilization of
various biological molecules via bioconjugation chemistry. The
c(RGDfC) was efficiently and site-specifically conjugated on
the maleimide-terminated NPs in an oriented and homoge-
Figure 5. High sensitivity of Au-tripods for photoacoustic molecular imaging. (a) The top view of three-dimensional (3D) volume rendering of
photoacoustic images of an agarose phantom containing decreasing number of U87MG cancer cells exposed to RGD-Au-tripod at different
wavelengths (670, 700, 725, 750, 800, 850, 900 nm). The inhomogeneous signal inside wells is due to possible aggregation of cells. (b) Quantitative
analysis of the photoacoustic signal (relative to the background signal) from the phantom (n = 3). (c) RGD-Au-tripod ranging in concentrations
from 390 pM to 12.5 nM were injected subcutaneously into the flank of living mice (n = 3) and scanned with photoacoustic instrument. (d,e)
Picomolar photoacoustic detection of tripods in living mice. The coronal view (d) of 3D volume rendering of photoacoustic images of subcutaneous
inclusions. The skin is visualized in the ultrasound image (gray-scale images), which is overlaid with photoacoustic images (green-scale images). (f,g)
Three-dimensional volume rendering of photoacoustic images (green) and ultrasound images (brown) of subcutaneous inclusion. a.u. = arbitrary
units. (h) Photoacoustic signals recorded in vivo increased linearly with the tripod concentration (R2 = 0.96, n = 3 mice, data represent mean ± SD).
The background level represents the endogenous signal measured from tissues. (i) Quantitative analysis of the photoacoustic signal (relative to the
background signal) (mice n = 3).
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neous fashion. In order to track the RGD-Au-tripods in vivo by
PET, the radioactive metal chelator, 2-(4-isothiocyanatoben-
zyl)-1,4,7-triazacyclononane-1,4,7-triacetic acid (p-SCN-Bn-
NOTA) was further conjugated to the surface of RGD-Au-
tripods in a well-defined manner for 64Cu radiolabeling. The
hydrodynamic size change and the corresponding change in ζ
potentials of modified Au-tripods clearly confirmed the efficient
conjugation of the c(RGDfC) peptide to the nanoparticles (SI
Figure S25 and Table S5−S8). RGD-Au-tripods also showed
excellent stability under physiological conditions. There were
no significant size changes or aggregation in the presence of the
mouse serum after 48 h at 37 °C (SI Figure S27). We also
validated the targeting ability of RGD-Au-tripods to αvβ3-
positive U87MG cells in vitro by determining their cellular
uptake using TEM and inductively coupled plasma mass
spectrometry (ICP-MS) analysis (SI Figures S28 and S29).
In order to obtain a better understanding of the in vivo
behavior of Au-tripods and study their potential toxicity, we
carried out a pilot preclinical animal toxicity study to assess the
potential toxicity of tripods to pave the way for their clinical
translation. Both hematology and serum biochemistry analyses,
and histologic and microscopic examination revealed that no
evidence of significant acute toxicity was observed and the
tripods are likely highly biocompatible in small living subjects
(SI Figures S35−S37).
Pharmacokinetics and Biodistribution of Au-Tripods.
The pharmacokinetics, biodistribution, and tumor-targeting
ability of Au-tripods were investigated in small living animals.
As described in the previous section, the water-soluble Au-
tripods were coated with a layer of functional PEG chains.
Quantification of grafted PEG density on PEGylated Au-tripods
was performed using spectrophotometric analyses of free
amines on the PEGylated Au-tripods (SI Table S6). Typically,
the density of amine groups on Au-tripod (PEG 3400 coating)
was 0.966 ± 0.07 number/nm2; the ratio of amine groups to a
single tripod was 757 ± 56. The chelating agent NOTA was
attached to the terminal of PEG chains for PET radionuclide
64Cu. Importantly, the 64Cu radiolabels on the tripods remained
intact on the tripods even though they were incubated in the
mouse serum over 24 h.
The U87MG tumor-bearing mice (n = 4) were tail-vein
injected with 64Cu−Au-tripod, followed by small animal PET
scans at different time points (1, 2, 4, 24, and 48 h). PET
imaging results revealed nonspecific uptake of PEGylated
tripods by the liver, spleen, and even kidney (Figure 4a and SI
Figures S30−S32), but minimum accumulation in the muscle
or other major organs. Although most of the tripods were
eliminated through hepatic excretion, the kidney retention of
radio-labeled tripods over time suggested that the renal
excretion could be an additional clearance route for tripods in
mice. Since the heart acted as a cardiac blood pool, the signals
from the heart were used as indicators to calculate the blood
circulation time. The PEGylated tripods showed slow systemic
clearance because of a long blood circulation time (t1/2 = 2.29
h), making themselves more available for distribution to target
tissues via the enhanced permeability and retention (EPR)
effect.
Targeting Characteristics of RGD-Au-Tripods. In order
to target the integrin αvβ3 for imaging tumor angiogenesis and
metastasis, the Au-tripods were conjugated with both p-SCN-
Bn-NOTA for 64Cu labeling and c(RGDfC) for tumor
targeting. The numbers of NOTA on the RGD-tripod were
determined by an isotope dilution assay and typically equaled
54.5 ± 3.3.44 The conjugated RGD was actually determined by
measuring the differences in concentration of RGD using
HPLC before and after addition of Au-tripods during the
coupling reaction. The ratio of RGD to NOTA on Au-tripods
was 8.2 ± 0.5. The targeting ability and specificity of RGD-Au-
tripods for the αvβ3 integrin were evaluated in the U87MG
tumor-bearing mice (n = 4). The representative coronal and
transverse PET images of a mouse acquired at 1, 4, 24, and 48 h
after tail vein injection of 64Cu-RGD-Au-tripods, 64Cu−Au-
tripods, or 64Cu-RGD-Au-tripods coinjected with a blocking
dose of c(RGDfC) are shown in Figure 4. Quantitative analysis
showed that tumor uptake of 64Cu-RGD-Au-tripods gradually
accumulated in the tumor between 1 and 24 h, reaching a
plateau at about 24 h post-injection, and then leveled off in the
next 24 h. The 64Cu-RGD-Au-tripods exhibited a significantly
high tumor uptake of ∼7.9% ID/g after 24 h post-injection,
which was more than 3 times higher than that of plain 64Cu−
Au-tripods (2.6% ID/g). Such high tumor accumulation was
attributed to the tumor specific binding affinity of RGD
functionalization on the tripods and their long blood circulation
time. In the control group, the tumor uptake was significantly
blocked when a blocking dose of c(RGDfC) was injected into
tumor-bearing mice along with 64Cu-RGD-Au-tripods. The
reduced tumor uptake was observed (3.8% ID/g after 24 h
post-injection), which is significantly lower than that of
unblocked one (P < 0.05). Interestingly, compared to plain
tripods, 64Cu-RGD-Au-tripods displayed much longer blood
circulation time (t1/2 = 10.3 h for
64Cu-RGD-Au-tripods vs t1/2
= 6.4 h for 64Cu−Au-tripods) and less RES uptake. 64Cu-RGD-
Au-tripods were also found to be excreted by both hepatobiliary
and renal routes, as indicated by the deposition of radioactivity
in the kidney and the gastrointestinal tract (b and e of Figure
4), which were also confirmed by the tissue histology following
in vivo imaging (SI Figure S40).
To confirm the photoacoustic detection of tripods in tumor
cells, we incubated U87MG cells with RGD-Au-tripods for 2 h
under standard conditions. The cells with internalized RGD-
Au-tripods after incubation were washed and placed in agarose
phantom at increasing cell concentrations from 11.5 × 103 to
368 × 103 cells per well (n = 3 per group). Quantitative analysis
of the photoacoustic signals from the phantom revealed that the
minimum detectable number of tumor cells exposed to RGD-
Au-tripods could be as low as 11.5 × 103 (a and b of Figure 5,
and Figure S17 of SI). We observed a linear correlation
between the number of RGD-Au-tripod-loaded cells and the
corresponding photoacoustic signal. The photoacoustic signal
from the phantom when excited at 700 nm provided the best
sensitivity to detect tumor cells. Even at 900 nm, the signal was
still detectable for 50 × 103 of tumor cells.
To test the tripod’s PAI sensitivity in living mice, we
subcutaneously injected the right hind side of a mouse with 30
μL of RGD-Au-tripods mixed with Matrigel (n = 3) at
increasing concentrations of 0.39, 0.78, 1.56, 3.125, 6.25, and
12.5 nM. After the incision was solidified in place, the mouse
was placed on its left side (left lateral recumbent) and partially
embedded in the agarose gel covered with a water bath, and was
then scanned under the photoacoustic system. While the
ultrasound signals were used to reconstruct the mouse
anatomy, including skin and inclusion edges, the photoacoustic
signals showed the tripods contrast in the mice (Figure 5c−h).
Quantitative analysis of the photoacoustic signals from each
inclusion using a 3D region of interest drawn over the inclusion
revealed a linear correlation between the tripod concentration
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and the corresponding photoacoustic signal. Compared to the
tissue background, about 200 pM of RGD-Au-tripods
extrapolated from the signal-concentration curve provided the
equivalent photoacoustic signal as the tissue background.
Similar to PET imaging, the PAI imaging ability of RGD-Au-
tripods to αvβ3 integrin-positive tumor was evaluated in the
U87MG tumor-bearing mice (n = 3) (see Figure 6). Before the
injection, the photoacoustic and ultrasound images of the mice
were taken. Photoacoustic images with lateral step size of 0.25
mm were acquired at 700 nm wavelength. Following the
photoacoustic scan, an ultrasound image of the entire tumor
area was acquired. The U87MG tumor-bearing mice were then
injected with 100−200 μL of RGD-Au-tripods (200 pmol per
kg mouse body weight) in PBS through the tail vein. For the
receptor-blocking experiment, mice were coinjected with 21
μmol of c(RGDfC)/kg of mouse body weight and 100−200 μL
of RGD-Au-tripods (200 pmol per kg mouse body weight) in
PBS through the tail vein. After injection, photoacoustic images
were acquired at 700 nm at 0.5, 1, 2, and 4 h post-injection.
Quantitative analysis of the photoacoustic signal from the
tumor was done by drawing three-dimensional (3D) regions-of-
interest (ROIs) around tumors on the basis of the ultrasound
images. Since there was the background blood signal in each
photoacoustic scan, a subtraction image calculated at the 2-h
post-injection image minus the preinjection image is shown in
SI Figure S39 and was used to subtract out the background
hemoglobin signal and examine the differences between groups.
Mice injected with RGD-Au-tripods showed significantly higher
photoacoustic signal in the tumor compared with the blocking
group coinjected with RGD after 2 h post-injection.
Figure 6. Targeting of integrin αvβ3-postitive U87MG tumors in mice by RGD-Au-tripod. (a) The coronal, sagittal, and transverse views of 3D
volume rendering of photoacoustic images and ultrasound images of nude mice bearing U87MG tumors were obtained before injection or at 1, 4, 24,
and 48 h after intravenous injection of RGD-Au-tripod (200 pmol/kg of mouse body weight, or 2 mg/kg of mouse body weight). (b) The coronal,
sagittal, and transverse views of 3D volume rendering of photoacoustic images and ultrasound images of nude mice bearing U87MG tumors were
obtained before injection or at 1, 4, 24, and 48 h after coinjection of a blocking dose of c(RGDfC) (21 μmol of c(RGDfC)/kg of mouse body
weight) and RGD-Au-tripod (200 pmol/kg of mouse body weight, or 2 mg/kg of mouse body weight). Subtraction images were calculated at the 2-h
post-injection image minus the preinjection image (SI Figure S34). (c) Mice injected with RGD-Au-tripod showed significantly higher photoacoustic
signal than mice with coinjection of a blocking dose of c(RGDfC) and the same amount of RGD-Au-tripod (p < 0.001, two-sided Student’s t-test).
The error bars represent standard error (n = 3 per group). (d) The perspective views of 3D volume rendering of photoacoustic images (green) and
ultrasound images (brown) of tumors.
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Quantitative analysis showed that tumor uptake of RGD-Au-
tripods gradually accumulated in the tumor between 1 and 4 h,
reaching a plateau at about 2 h post-injection, and then leveled
off in the next 2 h. The mice injected with RGD-Au-tripods at 2
h post-injection showed more than 3 times higher photo-
acoustic signal in the tumor than the mice coinjected with RGD
and RGD-Au-tripods. The tumor tissue histology combined
with silver staining further confirmed the specific targeting
ability of RGD-Au-tripods toward U87MG tumors (SI Figure
S40).
■ DISCUSSION
We showed the ability to engineer and manipulate constitu-
tional nanocrystals at the nanometer-scale to build novel
nanotripods in a predictable and controlled manner. The
construction of Au-tripods involved a set of nucleation
reactions and epitaxial growth processes, which are controlled
by surface diffusion.45,46 As solid-state analogues of multifunc-
tional organic molecules, Pt nanocubes could be used as
building blocks to construct sophisticated hybrid architec-
tures.38,41 Although Sun and co-workers provided an important
insight in the formation of various branched NPs,41 the
stochastic simulation in two dimensions inevitably overlooked
certain configurations of constructed nanostructures. The
selective growth of a heterogeneous nanocrystal phase onto
certain regions of nanocrystal seeds depends on the surface
potential and lattice matching.46 We found that regioselectivity
of the heterogeneous nucleation on cubic Pt seeds plays an
important role on the formation of nanotripods (SI Schemes S1
and S2). Considering the possible nucleation regions and steric
effect, 6.5 nm cubic seeds exclusively resulted in the formation
of uniform Au-tripods with high yield and improved quality by
sequentially applying a set of known nucleation reactions and
epitaxial growth processes.
The theoretical calculation coupled with experimental results
on such anisotropic tripod nanostructures was used as a guide
for the design and fabrication of PAI nanoprobes. We
successfully identified tripods with two possible configurations
as high absorbance nanomaterials from various gold multipods
using a numerical simulation analysis. The enhancement of the
electric field on the surface of Au-tripods is due to the
occurrence of coupled plasmons at the edges of tripods and the
junctions between gold nanocrystals on the Pt cubes.
Optimizing the geometrical configurations of gold nanocrystals
on the Pt cube could improve the plasmon resonances of Au-
tripods. The measured absorption spectrum of Au-tripods was
identified by the calculated FDTD spectrum. Due to an obvious
increase in the cross section of Au-tripods on a per-weight basis
compared to that of the gold rods, Au-tripods could generate
more contrast on PA images within the NIR region. Among
nanoparticle-based PA contrast agents, Au-tripods exhibit
superior optical properties in the NIR region, and more
importantly, they have exceptionally small sizes, which are
distinctive advantages over traditional gold-based NPs or
carbon nanotubes for in vivo molecular imaging.15,24,47
We have successfully validated novel Au-tripods as multi-
modality probes for in vivo molecular imaging (PAI and PET).
The in vivo biodistribution of Au-tripods favorable for living
subject imaging was confirmed by 64Cu radiolabeling and
imaging their localization over time using PET. After
intravenous administration, the Au-tripods accumulated in
liver and spleen, suggesting that the hepatic excretion is a major
route of elimination of Au-tripods. Interestingly, the kidney
retention of Au-tripods over time revealed that the renal
excretion could be an additional clearance route for Au-tripods.
Considering the anisotropic shape of Au-tripods [the thickness
of tripods is close to the renal clearance threshold (less than 7
nm)], it is possible for Au-tripods to be cleared to some extent
through the renal system.48,49 The PAI signals were linearly
correlated with their concentrations after subcutaneous
injection. Intravenous administration of RGD-Au-tripods to
U87MG tumor-bearing mice showed remarkably higher
contrast in tumors than competitive injection controls even at
subnanomolar concentrations. PAI results correlated well with
the corresponding PET images. Quantitative biodistribution
data revealed that 7.9% ID/g of RGD-Au-tripods accumulated
in the U87MG tumor after 24 h post-injection, but an obvious
decrease in RES uptake (low liver and spleen accumulation,
Figure 4) of RGD-Au-tripods was observed during the imaging.
It is clear that their tumor uptake was higher than most of
traditional gold-based NPs for in vivo molecular imaging,24,47
probably due to their unique anisotropic shape and relatively
small size. A pilot mouse toxicology study confirmed that no
evidence of significant acute and systemic toxicity was observed
in histopathological examination.
■ CONCLUSION
By sequentially applying a set of nucleation reactions and
epitaxial growth processes, we herein developed a control and
stepwise strategy to build novel anisotropic Au-tripods with
predesigned shape, high yield, and excellent quality. These Au-
tripods exhibit superior optical and physical properties
compared to their counterparts with regular architectures. We
showed the ability to tune their shape-dependent plasmon
resonances to the NIR window without compromising their
pharmacokinetic profile. Our strategy opens up novel ways to
enable the creation of sophisticated nanostructures with
predetermined optical and physical properties for specific
biomedical applications. Moreover, our study suggests that
highly selective and sensitive detection of cancer cells in a living
subject is possible using molecular specific Au-tripods as PAI
contrast agents. The functionalized RGD-tripods showed
significantly enhanced photoacoustic contrast effect in both
phantom and small animal imaging experiments. Functional
and molecular information of the tumor with high spatial
resolution was further obtained by PAI, which correlated well
with the corresponding PET quantification. Due to their
excellent biocompatibility and stability in a biological environ-
ment, ease of functionalization, passive and activated targeting
capabilities and potential hepatic and renal clearance, the Au-
tripods represent a new generation of a nanoplatform for
biomedical research and personalized therapy.
■ METHODS AND MATERIALS
Materials. The integrin αvβ3 targeting peptide cyclo (Arg-Gly-Asp-
D-Phe-Cys) (cRGDfC) was purchased from Peptides International,
Inc. (Louisville, KY). The p-SCN-Bn-NOTA was purchased from
Macrocyclics, Inc. Hydrogen tetrachloroaurate(III) hydrate (HAuCl4)
and platinum(II) acetylacetonate (Pt(acac)2) was ordered from Strem
Chemicals, Inc. N-Hydroxysuccinimide (NHS), N-hydroxysulfosucci-
nimide (sulfo-NHS), succinimidyl 4-(N-maleimidomethyl) cyclo-
hexane-1-carboxylate (sulfo-SMCC), and 1-ethyl-3-(3-dimethylamino-
propyl) carbodiimide, hydrochloride (EDC) were purchased from
Thermo Fisher Scientific. All other chemicals were purchased from
Sigma-Aldrich. Other solvents and chemicals were used as received. All
buffers and media were purchased from Invitrogen Corp. Deionized
water was obtained from a Millipore Milli-DI Water Purification
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system. The dialysis membrane tubing (MWCO: 12,000−14,000, and
100,000) were purchased from Spectrum laboratories.
Size Tuning of Cubic Pt NPs. The size of various cubic Pt NPs
was successfully tuned by adjustment of the reaction conditions in a
precise manner. Monodisperse Pt seeds were synthesized by thermal
decomposition of platinum precursor [Pt(acetylacetonate)2, Pt-
(acac)2], in 1-octadecene solution containing a trace amount of iron
pentacarbonyl [Fe(CO)5], which facilitates a fast nucleation and
improves the homogeneous growth of platinum crystals.40 The shape
and size of Pt NPs are dependent on the reaction temperature at which
a trace amount of Fe(CO)5 was injected. Multiple stepwise seed-
mediated growth processes were applied to obtain monodisperse Pt
nanocubes. The detailed synthesis procedure is described in the SI
Methods.
Synthesis and Surface Modification of Au-Tripods. The gold
precursor (hydrogen tetrachloroaurate, HAuCl4, 100 mg, 0.29 mmol)
was dissolved in 20 mL of 1-octadecene (ODE) containing 2 mL of
oleylamine under nitrogen protection. After stirring at room
temperature for 5 min, the solution was heated up to 80 °C. Twenty
milligrams of 6.5 nm freshly synthesized Pt NPs (dispersed in 1 mL of
hexane) was quickly injected into the above solution. The resultant
mixture was then heated up to 110 °C and kept at this temperature for
one hour before it was cooled down to room temperature. The
solution finally turned to gray-purplish color, indicating the formation
of gold branched nanostructures. The particles were precipitated out
by adding 30 mL of isopropanol and collected by a centrifuge (3000
rcf, 5 min). The resultant particles were redispersed in 5 mL of hexane
and then precipitated out by adding ethanol. This purification step was
repeated twice to remove the extra surfactant and ODE. The final
product (Au-tripods) was dispersed in 10 mL of hexane in the
presence of 0.01 mL of oleylamine for further use.
Surface PEGylation of Au-tripods is described in detail in the SI
sections A.4, B.2, C.5, and C.6. Briefly, the Au-tripods (10 mg) were
suspended in 3 mL of a chloroform solution of bidentate thiol-
termined PEG chains (O-(3-aminopropyl)polyethylene glycol lipoate
amide, LP-PEG-3400-NH2, 0.02 mmol, SI section A.3). After stirring
at room temperature for 24 h, PEGylated Au-tripods were precipitated
by adding 20 mL of hexane, collected by a brief centrifugation, and
dried under the nitrogen gas flow. PEGylated Au-tripods were then
dispersed in water, and the unbound PEG and any other excess
reagents were removed by dialysis against water or phosphate-buffered
saline (PBS) (10 mM, pH 7.4) by dialysis tubing (Spectrum Spectra/
Por dialysis membrane tubing, MWCO = 12 KDa). Any impurity or
precipitate was removed by a 0.22 μm syringe filter. The final gold or
platinum concentration of PEGylated Au-tripods was measured by
inductively coupled plasma mass spectrometry (ICP-MS) analysis.
Those NPs were further characterized with transmission electron
microscopy (TEM), UV−vis absorption spectroscopy, and dynamic
light scattering (DLS) (SI sections B.2, B.3, B.5, and sections C.4,
C.6).
Conjugation of Au-tripods with cRGD (RGD-Au-tripods) is
described in detail in the SI Sections A.5, C.6, and C.7. Typically,
The cross-linker solution, the water-soluble Au-tripods (100 nM, 0.5
mL, 5 × 10−11 mol, see the determination of concentrations of tripods
and rods in SI section C.3) in 10 mM PBS (pH = 7.2) were incubated
with the cross-linker solution (sulfo-SMCC [0.5 mg, 1.5 μmol], was
freshly prepared in 15 μL of DMSO) for 2 h at room temperature.
After removal of excessive sulfo-SMCC and byproducts using a PD-10
column (GE Healthcare, Piscataway, NJ), the resultant thiol-active Au-
tripods were concentrated to the final volume of 0.5 mL with a
centrifugal-filter (Amicon centrifugal filter device, MWCO = 30 kDa)
and were incubated with the cRGDfC stock solution (50 μL of 5 mM
in the degassed water, 0.25 μmol, the final RGD concentration in the
mixture was 0.5 mM) with stirring. The conjugation reaction
proceeded for 24 h at 4 °C. After the uncoupled RGD and byproducts
were removed through PD-10 column, the resultant product, RGD-
Au-tripods, was concentrated by a centrifugal-filter (Amicon
centrifugal filter device, MWCO = 30 KDa) and stored at 4 °C for
one month without losing targeting activity. The final RGD-Au-tripods
was reconstituted in PBS and filtered through a 0.22 μm filter for cell
and animal experiments. The gold and platinum concentrations of
RGD-Au-tripods were measured by ICP-MS analysis.
The process to conjugate the tripods with both RGD and NOTA
was similar to the conjugation of tripods and RGD, except that sulfo-
SMCC solution was mixed with NOTA aqueous solution in the first
step before being added into the tripod solution. Briefly, The sulfo-
SMCC (0.5 mg, 1.5 μmol) was dissolved in 15 μL of DMSO and
mixed with 4.5 μL of p-SCN-Bn-NOTA solution in the water (33 mM,
0.15 μmol). The ratio of SMCC to NOTA was optimized according to
the specific activity of radioactive tracer-labeled NPs (SI section C.7).
Small Animal PET Imaging. PET imaging was carried out on a
microPET R4 rodent model scanner (manufactured by CTI Concorde
Microsystems, Knoxville, TN) as previously reported.50−52 PET scans
were performed at 1, 2, 4, 24, and 48 h post-injection (p.i.). U87MG
tumor-bearing mice were divided into several injection groups (4 mice
per each group) to evaluate differences in specific targeting and
biodistribution of Au-tripods and RGD modified tripods (SI section
A.5 and C.7). For the tripod groups, each mice was injected with 3.7
MBq of 64Cu-RGD-Au-tripod (200 pmol/kg of mouse body weight, or
2 mg/kg of mouse body weight, normally 5 pmol per each mouse) in
100−200 μL PBS via the tail vein. For the receptor-blocking
experiment, U87MG tumor-bearing mice were coinjected with 12
mg of c(RGDfC)/kg of mouse body weight and 100−200 μL of 64Cu-
RGD-Au tripod (200 pmol per kg mouse body weight) in PBS via the
tail vein. Prior to imaging, mice were anesthetized with isoflurane (5%
for induction and 2% for maintenance in house oxygen at 2 L/min).
Mice (4 mice per group) were placed in the prone position and near
the center of the field of view (FOV) of the scanner. The 5-min static
scans were obtained at the predetermined time points after post-
injection. All the PET images were then reconstructed by a two-
dimensional ordered-subset expectation maximization (OSEM)
algorithm with a spatial resolution of 1.66−1.85 mm.53 PET
quantifications were analyzed using both AsiPro and Amide image
processing software. PET quantification details are included in the SI.
Au-Tripod-RGD Tumor Targeting in Living Mice. The custom-
built photoacoustic instrument was described previously and is shown
in SI Figure S2.54−56 The photoacoustic characterizations of Au-
tripods were further determined by NEXUS 128 (Endra, MI). Two
groups of female nude mice (n = 3 in each group, 6−8 weeks old)
were inoculated subcutaneously at their right hind side with 5 × 106
U87MG cells in 50 μL of PBS. The tumors were allowed to grow to a
volume of 150−200 mm3. The mouse was placed on its left side (left
lateral recumbent) and partially embedded in the agarose gel covered
with a water bath (SI Figure S2), and was then scanned under the
photoacoustic system. Before the injection, the photoacoustic and
ultrasound images of the mice were taken. A photoacoustic image with
lateral step size of 0.25 mm was acquired using the 5 MHz transducer
at 670, 700, and 725 nm wavelength. Following the photoacoustic
scan, an ultrasound image was acquired using the 25 MHz transducer.
The U87MG tumor-bearing mouse was then injected with 100−200
μL of RGD-Au-tripods (200 pmol per kg mouse body weight) in PBS
through the tail vein using a butterfly catheter to avoid any position
change during the injection (50 μL of dead volume) (SI Figure S2B).
For the receptor-blocking experiment, mice were coinjected with 21
μmol of c(RGDfC)/kg of mouse body weight and 100−200 μL of
RGD-Au-tripods (200 pmol per kg mouse body weight) in PBS
through the tail vein. After injection, photoacoustic images (20 mm ×
20 mm) were acquired at 670, 700, and 725 nm with step size of 0.25
mm and at 0.5, 1, 2, and 4 h post-injection. Following the
photoacoustic scan, the ultrasound images were acquired to confirm
the scan area. The photoacoustic and ultrasound images were
analyzed, coregistered, and displayed using AMIDE software.
Quantitative analysis of the photoacoustic signal from the tumor was
done by drawing three-dimensional ROIs around the tumor on the
basis of the ultrasound images. After 4 h post-injection, the mice were
sacrificed, and tumors and tissues of interest were collected for TEM
(SI section B.1), elemental analysis (SI section B.5), and histology
study (SI section B.6).
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